Citi opened an “upside 90-day catalyst watch” on shares of Agilent (A) while keeping a Buy rating on the name with a $185 price target The share overhang of a potential transformational acquisition should be removed with Agilent’s deal for Biocare Medical, the analyst tells investors in a research note. Citi sees the stock’s multiple rebounding.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent to acquire Biocare Medical for $950M in cash
- M&A News: Agilent to Buy Biocare Medical for $950M — What Investors Should Know
- Agilent Announces Planned Retirement of Principal Accounting Officer
- Agilent price target lowered to $160 from $180 at Morgan Stanley
- Agilent Technologies Signals Steady Growth Amid Headwinds